Usefulness of measurement of tobramycin levels in the era of once daily iv-treatment

F. Brinkmann (Bochum, Germany), A. Schlegtendal (Bochum, Germany), S. Dillenhoefer (Bochum, Germany), C. Koerner-Rettberg (Bochum, Germany)

Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Session: Microbiology and antimicrobial strategies in cystic fibrosis
Session type: E-poster session
Number: 691
Disease area: -

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Brinkmann (Bochum, Germany), A. Schlegtendal (Bochum, Germany), S. Dillenhoefer (Bochum, Germany), C. Koerner-Rettberg (Bochum, Germany). Usefulness of measurement of tobramycin levels in the era of once daily iv-treatment. 691

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis.
Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease
Year: 2021

Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling
Source: Eur Respir J 2012; 39: 1537-1538
Year: 2012

Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin
Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019
Year: 2020

Evaluation of patient adherence to tuberculosis treatment by measuring drug metabolites in urine
Source: Eur Respir J 2004; 24: Suppl. 48, 649s
Year: 2004

Lack of penetration of amikacin into saliva of tuberculosis patients
Source: Eur Respir J, 51 (1) 1702024; 10.1183/13993003.02024-2017
Year: 2018

Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 126s
Year: 2001

Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP)
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001

Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules
Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019
Year: 2019

Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1
Year: 2004

Clinical pharmacology study of a new tobramycin solution for nebulisation
Source: Eur Respir J 2005; 26: Suppl. 49, 729s
Year: 2005

Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis
Source: Virtual Congress 2020 – Tuberculosis: part 1
Year: 2020

Plasma DNA concentration and integrity measurement for NSCLC diagnostics and radical therapy effectiveness monitoring
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012

Influence of a combination therapy versus steroid monotherapy on FeNO
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010

The role of serum rifampicin level on antituberculosis treatment outcome
Source: Eur Respir J 2006; 28: Suppl. 50, 848s
Year: 2006

No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo
Source: Eur Respir J 2003; 22: Suppl. 45, 335s
Year: 2003

Substantial time reduction in diagnosis of Mycobacterium tuberculosis rifampicin and isoniazid resistance by the application of a DNA strip hybridization assay in clinical samples
Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis
Year: 2012

Comparison of methods for assessment of physical activity level in daily life in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 666s
Year: 2004

Long-term omalizumab treatment – do drug concentration levels count?
Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Year: 2020

In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles
Source: International Congress 2015 – Lung function: waiting to exhale...
Year: 2015